^
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive
:
A2
Servier Press Release - 5d
dMMR/MSI-H + TMB-L
Cholangiocarcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
PTEN mutation + MSI-H/dMMR
Cholangiocarcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
FGFR2 rearrangement
Cholangiocarcinoma
pemigatinib
Sensitive
:
A1
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive
:
A1
No biomarker
Cholangiocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Cholangiocarcinoma
gemcitabine
Sensitive
:
A2
No biomarker
Cholangiocarcinoma
BGJ398
Sensitive
:
B
FGFR2 rearrangement
Cholangiocarcinoma
TAS 120
Sensitive
:
B
FGFR2 fusion
Cholangiocarcinoma
TAS 120
Sensitive
:
B
HER-2 expression
Cholangiocarcinoma
trastuzumab + lapatinib
Sensitive
:
B
RET fusion
Cholangiocarcinoma
pralsetinib
Sensitive
:
C1
BRCA2 mutation
Cholangiocarcinoma
olaparib
Sensitive
:
C1
BRCA1 mutation
Cholangiocarcinoma
olaparib
Sensitive
:
C1
FGFR3 mutation
Cholangiocarcinoma
erdafitinib
Sensitive
:
C1
FGFR2 mutation
Cholangiocarcinoma
erdafitinib
Sensitive
:
C1
NTRK3 fusion
Cholangiocarcinoma
larotrectinib
Sensitive
:
C1
NTRK2 fusion
Cholangiocarcinoma
larotrectinib
Sensitive
:
C1
NTRK1 fusion
Cholangiocarcinoma
larotrectinib
Sensitive
:
C1
BRAF V600
Cholangiocarcinoma
vemurafenib
Sensitive
:
C1
MSI-H/dMMR
Cholangiocarcinoma
pembrolizumab
Sensitive
:
C1
BRAF V600E
Cholangiocarcinoma
trametinib + dabrafenib
Sensitive
:
C1
NTRK2 fusion
Cholangiocarcinoma
entrectinib
Sensitive
:
C1
NTRK3 fusion
Cholangiocarcinoma
entrectinib
Sensitive
:
C1
NTRK1 fusion
Cholangiocarcinoma
entrectinib
Sensitive
:
C1
FGFR2 fusion
Cholangiocarcinoma
BGJ398
Sensitive
:
C2
FGFR2 translocation
Cholangiocarcinoma
pemigatinib
Sensitive
:
C2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our